Skip to main content
. 2021 Oct 13;12:726283. doi: 10.3389/fimmu.2021.726283

Figure 6.

Figure 6

Competitive inhibition of ACE2 by both anti-A antibodies and SARS-CoV-2 in blood group O patients. The SARS-CoV-2 and anti-A antibodies induced ACE2 downregulation. Ang-II can activate NF-κB pathway in AT1R-mediated inflammatory response, leading to the increased production of multiple inflammatory cytokines. Therefore, SARS-CoV2 had more difficulties to use ACE2 as the cellular entry receptor because of anti-A antibodies.